| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/28/2002 | CA2411924A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting proteinkinases |
| 02/27/2002 | EP1182206A2 Stabilized oligonucleotids and the use thereof |
| 02/27/2002 | EP1181390A1 27 human secreted proteins |
| 02/27/2002 | EP1181385A2 Modulation of gene expression in gastrointestinal inflammation |
| 02/27/2002 | EP1181382A2 Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| 02/27/2002 | EP1181381A2 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus |
| 02/27/2002 | EP1181376A2 Gene construct for prodrug activation encoding a heterologous, glycosylphophatidylinositol-modified carboxypeptidase g2 and a cell surface targeting signal peptide |
| 02/27/2002 | EP1181369A1 Four-helical bundle protein zsig81 |
| 02/27/2002 | EP1181367A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 02/27/2002 | EP1181366A1 Mammalian receptor proteins; related reagents and methods |
| 02/27/2002 | EP1181364A1 Lipid metabolism transcription factor |
| 02/27/2002 | EP1181363A1 Recombinant human mannan-binding lectin |
| 02/27/2002 | EP1181362A1 Methods and reagents for inhibiting angiogenesis |
| 02/27/2002 | EP1181361A2 Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna |
| 02/27/2002 | EP1181319A1 Dr4 antibodies and uses thereof |
| 02/27/2002 | EP1181318A2 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
| 02/27/2002 | EP1181316A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
| 02/27/2002 | EP1181315A1 LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES |
| 02/27/2002 | EP1181310A1 Chemokine receptor ccr3 antagonists |
| 02/27/2002 | EP1181304A1 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
| 02/27/2002 | EP1181303A1 50 human secreted proteins |
| 02/27/2002 | EP1181286A1 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides |
| 02/27/2002 | EP1181285A2 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 02/27/2002 | EP1181284A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use |
| 02/27/2002 | EP1181283A1 Diaminothiazoles and their use for inhibiting protein kinases |
| 02/27/2002 | EP1181282A2 Benzothiazinone and benzoxazinone compounds |
| 02/27/2002 | EP1181281A2 Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists |
| 02/27/2002 | EP1181275A1 Thio-oxindole derivatives |
| 02/27/2002 | EP1181269A1 Cell proliferation inhibitors |
| 02/27/2002 | EP1181057A1 Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| 02/27/2002 | EP1181055A2 Enzyme-activated anti-tumor prodrug compounds |
| 02/27/2002 | EP1181054A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| 02/27/2002 | EP1181053A2 Use of soluble costimulatory molecules to enhance immune responses |
| 02/27/2002 | EP1181052A1 Protein a based binding domains with desirable activities |
| 02/27/2002 | EP1181051A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF IMMUNOLOGICALLY-MEDIATED DISEASES USING i MYCOBACTERIUM VACCAE /i |
| 02/27/2002 | EP1181047A2 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 02/27/2002 | EP1181046A2 10-formyltetrahydrofolate dehydrogenase as therapeutical agent |
| 02/27/2002 | EP1181038A2 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
| 02/27/2002 | EP1181031A1 Novel antiangiogenic peptides |
| 02/27/2002 | EP1181025A2 Molecular complexes presenting high affinity binding with respect to monocyte derived cells and their uses in therapy |
| 02/27/2002 | EP1181022A1 Medicinal compositions and their method of preparation |
| 02/27/2002 | EP1181017A1 Metalloprotease inhibitors |
| 02/27/2002 | EP1181013A1 Method and composition for the treatment of cancer |
| 02/27/2002 | EP1180938A2 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| 02/27/2002 | EP1003559B1 Immobilization of vitamin a acid by cationic polyelectrolytes |
| 02/27/2002 | EP0927178B1 Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| 02/27/2002 | EP0892789B1 Irreversible inhibitors of tyrosine kinases |
| 02/27/2002 | EP0842193B1 Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone |
| 02/27/2002 | EP0836380B1 Fgf9 as a specific ligand for fgfr3 |
| 02/27/2002 | CN1337966A Hesperitin pro-forms with enhanced bioavailability |
| 02/27/2002 | CN1337961A Heteroaryl amidines, methyl amidiues and guanidines as protease inhibitors |
| 02/27/2002 | CN1337959A 2-(2,6-dioxopiperidin-3-yl)-isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
| 02/27/2002 | CN1337958A Compounds and methods for modulation of estroglen receptors |
| 02/27/2002 | CN1337956A New Morpholinobenzamide salts |
| 02/27/2002 | CN1337955A Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| 02/27/2002 | CN1337953A New thryoid receptor ligands and process II |
| 02/27/2002 | CN1337952A 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors |
| 02/27/2002 | CN1337949A Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid as TACE inhibitor |
| 02/27/2002 | CN1337944A Acetylenic beta-sulfonamido and phosphinic acid amide hydroxamic acid as TACE inhibitors |
| 02/27/2002 | CN1337931A Retinoid antagonists and use thereof |
| 02/27/2002 | CN1337886A Method for improved radiation therapy |
| 02/27/2002 | CN1337878A Methods for treating overian cancer, poly(phosphoester) compositions, and biodegradable articles for same |
| 02/27/2002 | CN1337877A Method of preparing stable suspension of insoluble microparticles |
| 02/27/2002 | CN1337850A Amide derivatives for antiangiogenic and/or antitumorgenic use |
| 02/27/2002 | CN1337402A Synthesis process of antineoplastic drug etoposide |
| 02/27/2002 | CN1337401A Thiophosphoryl amino acid ester compound and its prepn process |
| 02/27/2002 | CN1337400A Organic arsine compounds with the function of inducing cancer cell to die and their synthesis process |
| 02/27/2002 | CN1337254A Cancer-treating Chinese medicine and its prepn |
| 02/27/2002 | CN1337251A 抗癌胶囊 Anticancer Capsules |
| 02/27/2002 | CN1337243A Cancer preventing health tea made of garlic, pepper, chilli, tea and ginger |
| 02/27/2002 | CN1337228A Application of lipoic acid for improving biological utilization ratio of mineral salt |
| 02/27/2002 | CN1079833C Recombinant P53 adenovirus method and compositions |
| 02/27/2002 | CN1079796C Novel N-7-heterocyclyl pyrrolo [2,3-D] pyridines and their use |
| 02/27/2002 | CN1079792C 酶抑制剂 Inhibitors |
| 02/27/2002 | CN1079791C Vitamin D. analogues |
| 02/27/2002 | CN1079672C Oral liquid alendronate formulations |
| 02/26/2002 | US6350907 Matrix metalloprotease inhibitors |
| 02/26/2002 | US6350887 Chemical intermediates for anticarcinogenic agents |
| 02/26/2002 | US6350886 Anticarcinogenic agents |
| 02/26/2002 | US6350858 A polypeptide involved in controlling phosphate retention; diagnosis and therapy for chronic kidney failure, end stage kidney disease, uremic bone disease, and cancer |
| 02/26/2002 | US6350756 Useful for treating cancer; (20s) esters with an oxyalkanoic acid; |
| 02/26/2002 | US6350755 Peptidomimetic compounds that do not have a thiol moiety; therapy of arteriosclerosis and diabetic vascular pathologies; |
| 02/26/2002 | US6350747 Protein serine/threonine kinase and protein tyrosine kinase enzyme inhibitors; angiogenesis inhibitors; antitumor and antiproliferative agents |
| 02/26/2002 | US6350745 Thrombin inhibitors |
| 02/26/2002 | US6350744 Pyrmidine or pyridine derivatives; antiarthritic and antiinflammatory agents; cachexia treatment; interleukin and tumor necrosis factor inhibitors |
| 02/26/2002 | US6350741 Inhibitors of interleukin-1β converting enzyme |
| 02/26/2002 | US6350737 Platinum complex, its preparation and therapeutic application |
| 02/26/2002 | US6350593 Receptors for fibroblast growth factors |
| 02/26/2002 | US6350581 Tumor-associated antigen |
| 02/26/2002 | US6350464 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same |
| 02/26/2002 | US6350457 Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae |
| 02/26/2002 | US6350455 Administering to patient effective amount of botulinum toxin to treat hyperplasic adrenal medulla |
| 02/26/2002 | US6350451 Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction |
| 02/26/2002 | US6350446 Polypeptides with amino acid sequences for kidney failure |
| 02/26/2002 | US6350431 Light image contrast agent with chromopores linked with polyether |
| 02/26/2002 | CA2072484C Use of nadh or nadph against cancer and aids |
| 02/26/2002 | CA2057048C Vitamin d analogues |
| 02/26/2002 | CA2046801C Substituted pyrroles |
| 02/21/2002 | WO2002014554A2 The anti-neoplastic agent et-743 inhibits trans activation by sxr |
| 02/21/2002 | WO2002014536A2 Odulating multiple lineage kinase proteins |